FDA-Drug2026-07-29Class IICHEMICAL

Major Pharmaceuticals Levothyroxine Sodium 75 mcg tablets recalled for subpotency

LABEL MIX UPNationwide distributionDrugs

What this means

Major Pharmaceuticals issued a recall of Levothyroxine Sodium 75 mcg tablets because some batches do not contain the full labeled amount of active ingredient. This means the medication may not work as intended for treating thyroid conditions. The affected batches have expiration dates of July 2026 and December 2026.

  • Check if your Levothyroxine matches the recalled lot numbers (N02172A, N02172B, N02288A, N02288B for bags; N02172 or N02288 for blisters).
  • Do not stop taking your medication without talking to your doctor or pharmacist.
  • Contact your pharmacy or doctor if you have one of the recalled batches; they can provide a replacement.
  • Ask your pharmacy for the NDC numbers on your package if you need help identifying whether your supply is affected.
The agency's original wording
Hazard

Subpotent Drug

Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the USA.
Affected count
N/A
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Products
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. Distributed by Cardinal Health, Dublin, OH 43017. NDC Bag: 55154-3560-0; NDC Blister: 0904-6951-61

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0709-2026

More Major Pharmaceuticals recalls

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Free · One email a week · Unsubscribe anytime